arrow
H

Hisashi Hidaka

Kitasato University Medical Center
H指数:63
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reply to Comment on Randomized Controlled Trial of Endoscopic Ultrasound-Guided Liver Biopsy Versus Percutaneous Liver Biopsy for Obtaining Histologically Adequate Specimens

回复关于内镜超声引导肝活检与经皮肝活检获取组织学足够标本的随机对照试验的评论

2026-09-080
PRE
Reply to “Methodological Concerns Regarding the Primary Endpoint and External Validity in the Randomized Trial of EUS-Guided Versus Percutaneous Liver Biopsy”

回复“关于EUS引导与经皮肝活检随机试验中主要终点和方法学外部有效性的方法论关注”

2026-09-070
PRE
Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma in Early Real-World Clinical Practice: A Multicenter Analysis of Efficacy and Safety

纳武利尤单抗联合伊匹木单抗治疗不可切除肝细胞癌在早期真实世界临床实践中的疗效与安全性:一项多中心分析

Cancers
IF4.4
2026-08-280
OA
Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab

他汀类药物使用与不可切除肝细胞癌患者接受阿替利珠单抗–贝伐珠单抗治疗后的生存改善相关,但与无进展生存结局无关

2026-07-060
PRE
Rifaximin Improves Cognitive Performance and Reduces Cirrhosis-Related Adverse Events in Covert Hepatic Encephalopathy: A Randomized Controlled Trial

利福昔明改善隐匿性肝性脑病的认知功能并减少肝硬化相关不良事件:一项随机对照试验

2026-05-060
PRE
A Prospective Observational Study of AUDIT-Based Risk Stratification and Drinking Guidance Provided by Hepatologists in Patients with Alcoholic Liver Disease

一项关于酒精使用障碍识别测验(AUDIT)为基础的风险分层及肝科医生在酒精性肝病患者中提供的饮酒指导的前瞻性观察研究

2026-01-010
PRE
Guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd-Chiari syndrome in Japan

日本特发性门静脉高压症、肝外门静脉阻塞和budd-chiari综合征的诊断和治疗指南

2024-10-040
OA
Hepatic Mac2-BP expression depends on liver fibrosis and inflammation due to fat accumulation in patients with metabolic dysfunction-associated steatotic liver disease

代谢功能障碍相关脂肪性肝病患者肝脏Mac2-BP表达依赖于脂肪积累引起的肝纤维化和炎症

2024-09-101
PRE
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma
2024-07-040
PRE
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child-Pugh A category: A multicenter study

仑伐替尼联合射频消融序贯治疗可为不可切除、处于中期且肝功能分级为Child-Pugh A级的肝细胞癌患者带来生存获益:一项多中心研究

2024-07-020
PRE
Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
2024-04-167
PRE
New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease

慢性肝病Mac-2结合蛋白糖基化异构体定量测定的新化学发光酶免疫分析

2023-10-087
PRE